ZIM Laboratories (NSE:ZIMLAB, BOM:541400) has received Marketing Authorization from Australia's Therapeutic Goods Administration (TGA) for its central nervous system product, Rizatriptan Benzoate Orally Disintegrating Films, according to a Monday filing.
The approval was granted through its Australian subsidiary, ZIMTAS and marks the company's first regulatory approval in Australia, the filing said.
Rizatriptan is used for the acute treatment of migraine in adults. The approval paves the way for the commercial launch of the drug in Australia, the company said in the filing.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。